KALA Kala Pharmaceuticals, Inc.
Kala Pharmaceuticals, Inc. (KALA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $640.7K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Iwicki Mark T | Director | Sell | 154,894 | $0.81 | $125.5K | 103,540 −59.9% of holding | |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Sell | 967 | $0.82 | $793 | 28,906 −3.2% of holding | |
| Bazemore Todd | Director | Sell | 47,768 | $0.83 | $39.6K | 35,932 −57.1% of holding | |
| Brazzell Romulus K | SEE REMARKS | Sell | 46,748 | $0.83 | $38.8K | 35,952 −56.5% of holding | |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Sell | 32,230 | $0.83 | $26.8K | 29,873 −51.9% of holding | |
| Kharabi Darius | CHIEF BUSINESS OFFICER | Sell | 20,806 | $0.83 | $17.3K | 41,760 −33.3% of holding | |
| 2 fills | Sell | 513,607 | $1.38 | $710.7K | 425,006 −54.7% of holding | ||
| 2 fills | Sell | 216,801 | $1.60 | $346.0K | 887,973 −19.6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.